摘要
目的评价贝那普利治疗中国原发性高血压患者的疗效与安全性。方法全面检索PubMed、Embase、Cochrane、CBM、CNKI等数据库中1989-01-2010-12期间发表的相关研究,由2位研究者根据纳入和排除标准,独立选择符合标准的随机对照试验(RCT),并提取相关数据。采用Stata11软件进行统计分析。结果 34项试验符合纳入标准,共1503例原发性高血压患者应用贝那普利,剂量范围10～40mg/d。贝那普利单药治疗可降低患者收缩压24.4mmHg(95% CI21.7～27.1,P<0.01),舒张压15.7mmHg(95% CI14.2～17.1,P<0.01)。与钙拮抗剂相比,贝那普利降低收缩压的幅度略小3.4mmHg(P=0.08),而舒张压降低幅度相似(P=0.55)。贝那普利收缩压(P=0.58)和舒张压(P=0.43)的降低幅度与血管紧张素受体拮抗剂(ARB)相似。咳嗽是贝那普利治疗的主要不良事件,发生率为10.6%。血管性水肿罕见(0.2%)。结论贝那普利治疗中国原发性高血压患者安全有效。
Objective To evaluate the antihypertensive efficacy and safety of benazepril in Chinese hypertensive patient population. Methods We searched the Cochrane, PubMed, EMbase, CBM, and CNKI databases from January 1989 to November 2010 for relevant studies. Two investigators independently identified randomized controlled trials （RCT）according to the predefined inclusion and exclusion criteria, and then extracted data. Statistical analy- sis was performed by Stata 11 software. Results Thirty-four studies of benazepril at dosages from I0 to 40 mg daily with 1503 patients fulfilled the inclusion criteria. The weighted average reduction from baseline in mean systolic and diastolic blood pressure for benazepril monotherapy was 24.4 mm Hg （95% CI 21.7-27.1, P〈0.01} and 15.7 mm Hg （ 95% CI 14. 2- 17.1, P〈0.01 ）. Benazepril appeared to be inferior to CCB in lowering systolic blood pressure by 3.4 mm Hg （P=0.08） but not in lowering diastolic blood pressure （P=0.55）, and was similar as angiotensin-receptor blockers in lowering systolic （P=0.58） and diastolic blood pressure （P=0.43）. Angioedema was rare （0.2 % ） ; however, cough was rather common in patients on benazepril with a prevalence of 10.6%. Conclusion Benazepril is efficacious and safe in the management of hypertension in Chinese population.
出处
《中华高血压杂志》
CAS
CSCD
北大核心
2011年第11期1024-1031,共8页
Chinese Journal of Hypertension
